

This is a repository copy of *Activity-based probes for functional interrogation of retaining  $\beta$ -glucuronidases*.

White Rose Research Online URL for this paper:  
<https://eprints.whiterose.ac.uk/117420/>

Version: Accepted Version

---

**Article:**

Wu, Liang [orcid.org/0000-0003-0294-7065](https://orcid.org/0000-0003-0294-7065), Jiang, Jianbing, Jin, Yi [orcid.org/0000-0002-6927-4371](https://orcid.org/0000-0002-6927-4371) et al. (12 more authors) (2017) Activity-based probes for functional interrogation of retaining  $\beta$ -glucuronidases. NATURE CHEMICAL BIOLOGY. pp. 867-873. ISSN 1552-4450

<https://doi.org/10.1038/nchembio.2395>

---

**Reuse**

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

**Takedown**

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk) including the URL of the record and the reason for the withdrawal request.

1 Activity based probes for functional interrogation of  
2 retaining  $\beta$ -glucuronidases

3 *Liang Wu<sup>S#</sup>, Jianbing Jiang<sup>#</sup>, Yi Jin<sup>S#</sup>, Wouter W. Kallemeijn<sup>†</sup>, Chi-Lin Kuo<sup>†</sup>, Marta Artola<sup>‡</sup>,*  
4 *Wei Dai<sup>‡</sup>, Cas van Elk<sup>‡</sup>, Marco van Eijk<sup>†</sup>, Gijsbert A. van der Mare<sup>‡</sup>, Jeroen D. C. Codée<sup>‡</sup>,*  
5 *Bogdan I. Florea<sup>‡</sup>, Johannes M. F. G. Aerts<sup>†</sup>, Herman S. Overkleeft<sup>‡\*</sup>, Gideon J. Davies<sup>S\*</sup>*

6 <sup>†</sup>Department of Bioorganic Synthesis, Leiden Institute of Chemistry, Leiden University, P.O.  
7 Box 9502, 2300 RA Leiden, the Netherlands

8 <sup>‡</sup>Department of Medical Biochemistry, Leiden Institute of Chemistry, Leiden University, P.O.  
9 Box 9502, 2300 RA Leiden, the Netherlands

10 <sup>S</sup>York Structural Biology Laboratory, Department of Chemistry, University of York,  
11 Heslington, York, YO10, 5DD, UK

12

13 <sup>#</sup> L.W., J.J. and Y.J. contributed equally to this work

14 Corresponding authors: gideon.davies@york.ac.uk; h.s.overkleeft@chem.leidenuniv.nl

15

## 16 Abstract

17 Humans express at least two distinct  $\beta$ -glucuronidase enzymes involved in disease: *exo*-acting  $\beta$ -  
18 glucuronidase (GUSB), whose deficiency gives rise to mucopolysaccharidosis type VII, and *endo*-  
19 acting heparanase (HPSE), implicated in inflammation and cancers. The medical importance of these  
20 enzymes necessitates reliable methods to assay their activities in tissues. Herein, we present a set of  
21  $\beta$ -glucuronidase specific activity based probes (ABPs) which allow for rapid and quantitative  
22 visualization of GUSB and HPSE in biological samples, providing a powerful tool for dissecting their  
23 activities in normal and disease states. Unexpectedly, we find that the supposedly inactive HPSE  
24 proenzyme proHPSE is also labeled by our ABPs, leading to surprising insights regarding structural  
25 relationships between proHPSE, mature HPSE, and their bacterial homologs. Our results  
26 demonstrate the application of  $\beta$ -glucuronidase ABPs in tracking pathologically relevant enzymes,  
27 and provide a case study of how ABP driven approaches can lead to discovery of unanticipated  
28 structural and biochemical functionality.

## 29 Introduction

30 Retaining  $\beta$ -glucuronidases are enzymes responsible for hydrolytic cleavage of  $\beta$ -linked glucuronides  
31 from polysaccharide and glycoconjugate molecules, with net retention of anomeric stereochemistry  
32 at the released glucuronide. Humans express at least two major retaining  $\beta$ -glucuronidases: *exo*-  
33 acting GUSB, responsible for cleaving  $\beta$ -linked glucuronides from the non-reducing end of diverse  
34 glycosaminoglycans (GAGs) in the lysosome, and *endo*-acting heparanase (HPSE), specifically  
35 responsible for breakdown of heparan sulfate (HS) in lysosomes and the extracellular matrix (ECM).  
36 Both enzymes are strongly implicated in disease processes: deficiency of GUSB is the basis of the  
37 autosomal recessive disease mucopolysaccharidosis type VII (MPSVII), also known as Sly syndrome<sup>1-  
38 3</sup>, whilst HPSE overexpression is linked to a variety of pathologies including inflammation and cancer  
39 metastasis<sup>4,5</sup>.

40 Although both GUSB and HPSE possess  $\beta$ -glucuronidase activity, these enzymes are dissimilar at the  
41 sequence level and fall under different families of the Carbohydrate Active enZymes (CAZY)  
42 classification scheme<sup>6</sup>: GH2 for GUSB and GH79 for HPSE. Structurally, human GUSB is a large  
43 homotetrameric assembly, with each protomer comprising a  $(\beta/\alpha)_8$  barrel domain, a jelly roll domain  
44 and an Ig constant chain like domain<sup>7</sup>. In contrast, HPSE is a heterodimer comprised of 8 kDa and 50  
45 kDa subunit chains, which fold to produce a  $(\beta/\alpha)_8$  barrel flanked by a smaller  $\beta$ -sandwich domain<sup>8</sup>.  
46 The mature HPSE heterodimer is formed by proteolytic removal of a 6 kDa linker peptide from a  
47 single chain proenzyme - proHPSE.

48 Given the importance of  $\beta$ -glucuronidases in human health and disease, a facile method to visualize  
49 and quantitate their activity would be of great utility. We have previously reported the  
50 development of activity based probes (ABPs) based upon the cyclophellitol aziridine scaffold, which  
51 can be used to specifically detect enzymatic activity for a range of glycosidases<sup>9-14</sup>. These probes  
52 provide valuable tools to rapidly determine enzyme activities within their native physiological  
53 contexts.

54 Herein, we unveil the synthesis of ABPs designed to selectively target and label retaining  $\beta$ -  
55 glucuronidases. We demonstrate the utility of these probes in quantitating  $\beta$ -glucuronidase activity

56 in a range of cell and tissue samples, via both fluorescence and chemical proteomics approaches.  
57 Unexpectedly, we find that a monosugar  $\beta$ -glucuronidase probe is sufficient to label not only *exo*-  
58 acting GUSB, but also *endo*-acting HPSE, despite binding just one of multiple subsites within the  
59 HPSE active site cleft. Furthermore, the supposedly inactive proHPSE proenzyme is also labeled by  
60 ABPs, prompting us to investigate the nature of proHPSE 'inactivation' by its 6 kDa linker, and how  
61 this structure relates to other GH79 enzymes. Our results demonstrate a wide ranging potential of  $\beta$ -  
62 glucuronidase ABPs as biological and biomedical tool compounds, and highlight the general power of  
63 ABPs for driving the discovery of novel biological insights<sup>15</sup>.

## 64 Results

### 65 Glucuronidase specific inhibitor and probe design

66 We have previously demonstrated cyclophellitol derived epoxides and aziridines to be powerful  
67 mechanism based inhibitors for retaining  $\beta$ -glucosidases<sup>16</sup>, due to their ability to specifically label the  
68 enzyme catalytic nucleophile, in a conformation resembling the covalent intermediate of glycoside  
69 hydrolase reactions. (**Fig. 1a, b**)<sup>17</sup>. Inhibition is typically tolerant to functionalization at the ring  
70 nitrogen of cyclophellitol aziridines, allowing fluorophore or biotin tagging to create inhibitor probes  
71 which can label specific glycosidases within complex biological mixtures<sup>18</sup>.

72 Conceptually, we envisioned that  $\beta$ -glucuronidase specific ABPs could be accessed from  
73 cyclophellitol by oxidation at the C6 equivalent position, to emulate the carboxylate of glucuronic  
74 acid (GlcUA). ABPs **1–4** are composed of such a  $\beta$ -glucuronide configured cyclophellitol aziridine,  
75 bearing a spacer from the aziridine nitrogen terminating in BODIPY-FL, a BODIPY-TMR analog, Cy5, or  
76 biotin respectively. Alongside these functionalized ABPs we also prepared azide substituted ABP **5**  
77 (the precursor of **1–4**), unsubstituted aziridine **6** and cyclophellitol-6-carboxylate **7**. (**Fig. 1c**;  
78 structures of additional compounds **8–16** used in this study are shown in **Supplementary Results**,  
79 **Supplementary Fig. 1**).

### 80 GlcUA ABPs target $\beta$ -glucuronidases *in vitro* and *in situ*

81 To assess the potency of our  $\beta$ -glucuronidase ABPs *in vitro*, we first turned to the *exo*-acting GH79  $\beta$ -  
82 glucuronidase AcGH79 from *Acidobacterium capsulatum*, whose activity is readily followed using the  
83 fluorogenic substrate 4-methylumbelliferyl-glucuronic acid (4MU-GlcUA)<sup>19</sup>. All compounds tested  
84 were effective inhibitors of AcGH79, with apparent IC50s in the low to sub nM range (**Table 1** left  
85 panel). Core ABP 'warhead' **6** inhibited AcGH79 with apparent IC50 of ~5 nM. This was potentiated  
86 by further functionalization: apparent IC50 of Cy5 substituted ABP **3** was ~1 nM, whilst **1, 2, 4** and **5**  
87 were all sub-nanomolar inhibitors of AcGH79. Apparent IC50 for epoxide **7** was ~34 nM, consistent  
88 with lower reactivity of the epoxide moiety compared to aziridines.

89 Kinetic parameters for inhibition of AcGH79 were determined using a continuous assay, whereby  
90 substrate and inhibitor react with enzyme simultaneously (**Supplementary Note 1**)<sup>20</sup>, allowing us to  
91 derive a combined inhibition parameter  $k_i/K_i$  for all ABPs tested.  $k_i/K_i$  values largely reflected the  
92 trend seen with IC50s, with the activity of core aziridine **6** potentiated by further functionalization,  
93 and epoxide **7** substantially less active than aziridines (**Table 1** middle panel, **Supplementary Fig. 2**).

94 Finally, we tested the ability of our probes to inhibit  $\beta$ -glucuronidases in live fibroblast cells. *In situ*  
95 apparent IC50s were determined for ABPs **2** and **3** to be in the low  $\mu$ M range ( $\sim$ 1.7 and  $\sim$ 1.8  $\mu$ M  
96 respectively). We were unable to determine *in situ* apparent IC50s for **1** or **4–7**, likely reflecting a  
97 limited ability of these compounds to permeate the cell membrane (**Table 1** right panel).

98 Fluorescent labeling of AcGH79 by ABP **1** was readily visualized after running on SDS-PAGE, and  
99 could be blocked by competition with **2–7**, 4MU-GlcUA, or iminosugar **8**. Labeling also was abolished  
100 by SDS denaturation of protein, in line with a mechanism-based mode of action requiring  
101 catalytically competent enzyme (**Supplementary Fig. 3a**).

102 To dissect the mechanistic mode of action of our probes, we obtained crystal structures of **5** in  
103 complex with wild type AcGH79, and an inactive AcGH79(E287Q) nucleophile mutant  
104 (**Supplementary Fig. 3b, c**). Both complexes showed a single molecule of **5** bound within the active  
105 site of AcGH79, with no labeling of off-target residues. In wild type AcGH79, reacted **5** was observed  
106 bound via C1 to the enzyme nucleophile (Glu287) in a  ${}^4C_1$  conformation, making identical non-  
107 covalent contacts as previously observed for GlcUA or 2F-GlcUA<sup>19</sup>. In the AcGH79(E287Q) mutant, **5**  
108 occupied the same active site position, but was instead found to adopt a  ${}^4H_3$  conformation, due to  
109 restricted rotation across the C1-C7 bond imposed by the aziridine. Notably, the  ${}^4H_3$  conformation  
110 observed for unreacted **5** is the same as that postulated for oxocarbenium-like transition states of  
111 retaining  $\beta$ -glycosidase substrates during hydrolysis (**Supplementary Fig. 3d**)<sup>21</sup>. The high affinities of  
112 cyclophellitol derived ABPs for their target enzymes may thus be in part due to their conformational  
113 mimicry of this transition state<sup>22</sup>.

#### 114 **ABP profiling reveals GUSB and HPSE as probe targets**

115 To determine the targets of retaining  $\beta$ -glucuronidase ABPs in complex biological samples, human  
116 splenic lysates (which we have previously shown to express a range of glycosidases<sup>10-12</sup>) were treated  
117 with one or more ABPs, resolved by SDS-PAGE, and labeled proteins visualized by fluorescent  
118 scanning (the typical ABP workflow is shown in **Supplementary Fig. 4**).

119 Several fluorescent bands were observed in samples treated with Cy5 ABP **3** which were absent in a  
120 mock (DMSO) control, and which could be competed for by biotin ABP **4** (**Fig. 2a**). Based on  
121 literature reports, we tentatively assigned the prominent double bands at  $\sim$ 78–80 kDa as full length  
122 and C-terminal truncated isoforms of GUSB<sup>23</sup>, and the lowest molecular weight band as the  $\sim$ 64 kDa  
123 isoform of GUSB<sup>24</sup>; these bands were also identified by an anti-GUSB western blot (**Supplementary**  
124 **Fig. 5a**). A band at  $\sim$ 60 kDa did not correspond with any known glucuronidases but could be  
125 abrogated by pretreatment with  $\beta$ -glucosidase ABP **9**, suggesting this was the lysosomal acid  $\beta$ -  
126 glucosidase GBA, which is specifically labeled by **9**<sup>12</sup>. Correspondingly, this  $\sim$ 60 kDa band was also  
127 absent in splenic lysates from patients with Gaucher disease, which is characterized by lack of GBA  
128 activity.

129 To unambiguously establish the targets of our ABPs, we carried out a set of chemical proteomics  
130 experiments using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS).  
131 Lysates from normal or Gaucher spleens were incubated with biotin ABP **4**, with or without  
132 pretreatment using **9**. Labeled proteins were then pulled down using streptavidin beads, and  
133 processed using a standard proteomics workflow, utilizing both 'in-gel' and 'on-bead' digest

134 protocols (**Supplementary Fig. 4**). The 'on bead' digest protocol was also applied to human  
135 fibroblast lysates, in order to assess the efficacy of ABP pulldown in another tissue type.

136 Proteomic profiling using the 'in-gel' digest protocol identified GUSB as the predominant splenic  
137 protein labeled by **4**, with particular enrichment in bands corresponding to those previously  
138 identified by **3** (**Fig. 2b**). As with fluorescent labeling, we detected GBA at ~60 kDa, which was  
139 abrogated by pretreatment with **9** and reduced in Gaucher spleen. 'In-gel' proteomic results were  
140 largely mirrored by those from the 'on bead' protocol, which showed GUSB to be the most abundant  
141 glycosidase after pulldown from spleen, and also highly enriched after pulldown from fibroblast  
142 (**Supplementary Data Set 1**). Covalent modification of the GUSB nucleophile (Glu540) by **4** was  
143 directly characterized by MS/MS fragmentation of the 13 amino acid peptide containing this residue  
144 (**Supplementary Fig. 5b**).

145 The high sensitivity of proteomic profiling enabled detection of two glycosidase enzymes in splenic  
146 lysates not observed by fluorescent labeling with **3**:  $\beta$ -galactosidase GLB1, and *endo*  $\beta$ -glucuronidase  
147 HPSE. Both enzymes were substantially less abundant in pull-down fractions compared to GUSB, as  
148 estimated by their exponentially modified protein abundance index (emPAI) scores (**Supplementary**  
149 **Fig. 5c**). We theorized that GLB1 was likely a weak non-specific target of **4**, as it showed the lowest  
150 emPAI of all detected glycosidases despite robust transcriptional expression reported in spleen  
151 (**Supplementary Fig. 5d**)<sup>25</sup>, and strong histochemical staining of  $\beta$ -galactosidase activity in  
152 mammalian splenic tissues<sup>26</sup>. In contrast, HPSE is predicted to be poorly expressed in spleen by  
153 transcriptomics, yet showed a higher emPAI score than GLB1 after pull-down by **4**. These  
154 observations suggested HPSE was a *bona fide* target of our ABPs, despite the inability of the  
155 monosugar probes to make a full complement of interactions within the HPSE *endo*-acting substrate  
156 cleft, which normally accommodates at least a trisaccharide<sup>27</sup>.

#### 157 **$\beta$ -glucuronidase ABPs label endogenous HPSE and proHPSE**

158 Following the surprising discovery that splenic HPSE was labeled by **4**, we re-examined fluorescent  
159 labeling of HPSE in cells and tissues expressing higher levels of HPSE. In the first instance, we induced  
160 HPSE overexpression in HEK293T cells, and probed harvested lysates at set intervals. Two plasmids  
161 were tested: pGEn1-HPSE, encoding for N-His-Strep-TEV tagged proHPSE, and pGEn2-HPSE, encoding  
162 for N-His-Avitag-eGFP-TEV tagged proHPSE; HEK293T cells subsequently process these proHPSE  
163 precursors to mature HPSE.

164 Using **3**, we tracked increasing expression of a band at ~50 kDa, corresponding to the mass of the  
165 large HPSE subunit, which contains the nucleophile Glu343 (**Fig. 3a**)<sup>28</sup>. Unexpectedly, we also  
166 detected bands at ~75 kDa for pGEn1-HPSE and ~100 kDa for pGEn2-HPSE, corresponding to the  
167 masses of proHPSE chains expressed by these plasmids. Western blotting using an anti-HPSE  
168 antibody confirmed these bands to be proHPSE, indicating that **3** also labeled the supposedly  
169 inactive proenzyme. Initial comparison of band intensities from ABP labeling using **3** vs. western  
170 blotting suggested that **3** labeled mature HPSE with greater efficiency than it labeled proHPSE.  
171 However, the opposite trend was observed when using purified recombinant proHPSE  
172 (**Supplementary Fig. 6a**), suggesting that the majority of proHPSE overexpressed by HEK293T cells  
173 was likely inactive.

174 HPSE maturation is thought to be mediated by the cysteine protease cathepsin L (CTSL), through  
175 multiple proteolytic cleavages of the 6 kDa linker peptide<sup>29</sup>. We tested the effect of CTSL inhibitors  
176 CAA0225<sup>30</sup> (**10**), Z-FY(tBu)-DMK<sup>31</sup> (**11**) and leupeptin on proHPSE maturation in HEK293T cells by  
177 incubating cells transfected pGEn1-HPSE with CTSL inhibitors for 2 d and labeling lysates with **3**. In  
178 inhibitor treated cells, we observed modest but dose dependent accumulation of a band ~5 kDa  
179 below the principal proHPSE band, corresponding to loss of the unstructured N-His-Strep-TEV tag  
180 followed by blockade of further proteolysis, in line with the role of CTSL in HPSE maturation  
181 (**Supplementary Fig. 6b**). However, accumulation of mature HPSE was still detected in the presence  
182 of all inhibitors tested, suggesting either incomplete CTSL inhibition, or the presence of non-  
183 cathepsin mediated HPSE maturation pathways also utilized by HEK293T cells.

184 We also tracked internalization and processing of proHPSE to mature HPSE in fibroblasts, a process  
185 which may be utilized by cancer cells to increase their own levels of HPSE: by capturing and  
186 internalizing extracellular proenzyme<sup>32</sup>. Within 90 minutes of introducing proHPSE into culture  
187 medium, internalization and processing of HPSE by fibroblasts was detectable using **3** (**Fig. 3b**).  
188 These experiments demonstrate the ability of  $\beta$ -glucuronidase ABPs to detect and track key  
189 biological processes such as HPSE internalization and maturation.

190 Lastly, we reattempted fluorescent labeling of endogenous HPSE in human tissues. As splenic HPSE  
191 expression was below the fluorescent detection limit, we turned to platelets, which are known to  
192 contain high levels of mature HPSE<sup>33</sup>. Using **3**, we observed labeling of a band at ~50 kDa in platelet  
193 lysates corresponding to HPSE, in addition to the same GUSB bands previously detected in spleen  
194 (**Fig. 3c**). Comparison of fluorescence and western blotting intensities between platelet HPSE and a  
195 200 fmol recombinant standard suggested fluorescent sensitivity for recombinant HPSE to be in the  
196 fmol range, somewhat more sensitive than western blotting in our hands. Fluorescent HPSE  
197 detection in platelet lysates was slightly less sensitive, possibly due to the presence of competing  
198 protein targets or inactive HPSE *in situ*. 10 nM of **3** was sufficient to produce a detectable HPSE  
199 signal in platelets after 30 minutes (**Supplementary Fig. 6c**). Labeling of HPSE, but not GUSB, was  
200 also improved by the addition of NaCl (**Supplementary Fig. 6d**). Optimum labeling of HPSE by **3** was  
201 achieved at pH 4.5–5.0, consistent with literature reports of its optimum pH for enzymatic activity<sup>34</sup>.  
202 In contrast, optimum pH for labeling GUSB was higher than expected at pH ~5.5–6.0 (**Fig. 3d**),  
203 compared to its reported optimum for activity at the lysosomal pH ~4.5<sup>35</sup>. This unexpected pH of  
204 GUSB ABP labeling may be due to facile aziridine ring opening occurring independently of a  
205 protonated acid/base residue<sup>36</sup>. However, optimum labeling of GUSB at a non-lysosomal pH  
206 presents its own serendipitous advantages, allowing both GUSB and HPSE to be analyzed either  
207 jointly or independently of each other through modulation of labeling pH.

#### 208 **Competitive ABP labeling identifies HPSE specific inhibitors**

209 Because ABPs can detect a complete complement of enzymes in a cellular/environmental sample,  
210 competitive ABP labeling provides a powerful tool to assess inhibitor efficacy and specificity within a  
211 single experiment<sup>37</sup>. We sought to establish whether GlcUA ABPs could be used for the assessment  
212 of enzyme specific inhibitors, by testing platelet labeling at pH 5.0 (where both GUSB and HPSE  
213 react) in the presence of a set of known inhibitors.

214 In the presence of the monosaccharide-like  $\beta$ -glucuronidase inhibitor siastatin B<sup>38</sup>, both GUSB and  
215 HPSE labeling were abrogated in a dose-dependent manner, demonstrating the ability of this

216 molecule to outcompete ABP binding in both *endo*- and *exo*- acting enzymes. Using quantitated  
217 band intensities, IC50s for GUSB and HPSE labeling inhibition were measured to be ~3.3  $\mu$ M and ~6.7  
218  $\mu$ M respectively, indicating slightly greater affinity for GUSB by siastatin B (**Fig. 4a**).

219 In contrast, HPSE labeling in platelets was selectively inhibited by competition with heparin (**12**, IC50  
220 ~0.17 mg/mL, **Fig. 4b**), a large polysaccharide which cannot be accommodated by the *exo*- acting  
221 active site of GUSB. Selective inhibition was also observed upon competition with HS (**13**), the  
222 substrate of HPSE, albeit with slightly lower potency (**Fig. 4c**, IC50 ~0.50 mg/mL). Negligible  
223 inhibition was observed for N-Acetyl-O-desulfated heparin (**14**) (**Supplementary Fig. 7a**), highlighting  
224 the importance of sulfation for interactions between heparin/HS and HPSE. A lower degree of  
225 sulfation in HS vs. heparin may partly account for its slightly weaker abrogation of ABP labeling<sup>39</sup>.

226 We next tested labeling inhibition by GAGs with different linkages and sulfation patterns to heparin  
227 and HS. Hyaluronic acid (**15**) and chondroitin sulfate (**16**) both showed no inhibition of either HPSE  
228 or GUSB labeling at concentrations sufficient for inhibition by heparin/HS (**Supplementary Fig. 7b, c**),  
229 highlighting the critical role of sugar linkage and sulfation in interactions between GAGs and HPSE.  
230 Taken together, these assays provide proof of principle that GlcUA ABPs are amenable for use in a  
231 competitive format, to assess inhibition of specific  $\beta$ -glucuronidases within a mixture of related  
232 activities.

### 233 **Structural basis of HPSE and proHPSE ABP labeling**

234 To investigate how efficient labeling of *endo*-acting HPSE was achieved by a monosugar ABP, we  
235 obtained crystal structures of both wild type and nucleophile mutant (E343Q) HPSE in complex with  
236 ABP **5**. Complexes of HPSE with **5** were similar to those obtained with AcGH79, showing a single  
237 molecule of probe occupying the -1 subsite of the HPSE substrate binding cleft (nomenclature  
238 according to Ref. 40) in reacted <sup>4</sup>C<sub>1</sub> (wild type) or unreacted <sup>4</sup>H<sub>3</sub> (mutant) conformations  
239 (**Supplementary Fig. 8a**). The network of interactions made to the probe was highly similar between  
240 AcGH79 and HPSE, with the primary difference being a lack of interaction by HPSE to O4 of the  
241 probe, due to extension of its natural HS substrate towards this position (**Supplementary Fig. 8b**). A  
242 -1 subsite C6 carboxylate recognition motif, comprising 3 H-bonds from a tyrosine and two  
243 consecutive backbone amides, is highly conserved in GH79  $\beta$ -glucuronidases (Tyr 334, Gln293-  
244 Gly294 in AcGH79; Tyr391, Gly349-Gly350 in HPSE; Tyr 302, Gly261-Gly262 in the recently  
245 characterized heparanase from *Burkholderia pseudomallei*)<sup>41</sup>. This strong network of H-bonds to C6  
246 carboxylate likely offsets the absence of only a single H-bond to O4 of the ABP in HPSE compared to  
247 AcGH79, thus rationalizing robust labeling of HPSE by a monosaccharide probe that only occupies a  
248 single subsite within its extensive binding cleft. Additional binding affinity may also derive from the  
249 transition state like <sup>4</sup>H<sub>3</sub> conformation adopted by unreacted ABPs.

250 We next sought to solve the structure of proHPSE, in order to characterize the basis of its  
251 'inactivation' by the 6 kDa linker peptide, and to determine how  $\beta$ -glucuronidase ABPs are able to  
252 circumvent this. Herein, we report the first crystal structure of proHPSE in both apo and ABP  
253 complexed forms, which together with previously reported HPSE structures completes a structural  
254 characterization of the HPSE maturation process.

255 The proHPSE structure was similar to that of mature HPSE (RMSD: 0.52 Å over 451 C $\alpha$ ), with the  
256 same ( $\beta/\alpha$ )<sub>8</sub> and  $\beta$ -sheet domains clearly discernible. The 6 kDa linker (110-157) forms a large helical



257 domain which sits directly 'above' the active site cleft, blocking access to the bulky HS substrates of  
258 HPSE. The final loop of the linker leading into the 50 kDa subunit (His155-Lys159) is substantially  
259 more disordered than the rest of the protein, as evidenced by higher B-factors for these residues in  
260 the crystallographic model (**Supplementary Fig. 9a, b**). Mutation studies have established Tyr156 of  
261 the proHPSE linker to be critical for recognition by CTSL in the first step of HPSE maturation<sup>42</sup>.  
262 Disorder of the His155-Lys159 loop allows for unencumbered CTSL access to Tyr156 without  
263 disrupting preexisting secondary structures, consistent with the important role of Tyr156 in HPSE  
264 maturation.

265 Unexpectedly, steric blockage by the linker peptide was found to be incomplete in proHPSE, leaving  
266 a 'binding pocket' on the protein surface containing exposed catalytic nucleophile and acid/base  
267 residues, similar to the *exo*-acting active site of AcGH79 (**Fig. 5a**). When compared in a sequence  
268 alignment, the proHPSE linker corresponds to a loop in AcGH79, which forms the 'rear' face of its  
269 active site pocket, suggesting that whilst this sequence has expanded in the human enzyme,  
270 proHPSE still retains some structural characteristics reminiscent of a GH79 *exo*-glycosidase  
271 (**Supplementary Fig. 8c**). ABP **5** was found to bind to this proHPSE 'active-site pocket' in a  
272 configuration identical to that observed for HPSE. The O4 proximal position, vacant in HPSE, was  
273 occupied by His155 in proHPSE, contributed by the linker, which blocks off extension towards this  
274 position by HS substrates (**Fig. 5b, c**). The disordered proHPSE His155-Lys159 loop was slightly  
275 displaced upon binding **5** (~1.54 Å for Tyr156 C $\alpha$ ), due to steric clashes with the bound ABP  
276 (**Supplementary Fig. 9c**).

277 As with mature HPSE, proHPSE was inactive against the artificial fluorogenic substrate 4MU-GlcUA,  
278 indicating it does not possess any additional *exo*-glucuronidase activity against this substrate which  
279 is lost upon maturation (**Supplementary Fig. 8d**). To assess the accessibility of the proHPSE 'pocket'  
280 compared to mature HPSE, we conducted competitive ABP experiments against recombinant  
281 proHPSE and HPSE using **3**. As with platelets, siastatin B inhibited ABP labeling of both pro- and  
282 mature HPSE (**Supplementary Fig. 10a**), indicating it could efficiently occupy the 'binding pocket' of  
283 proHPSE as well as HPSE. In contrast, heparin only inhibited labeling of HPSE, albeit with lower  
284 efficacy than seen in platelets, due to more facile labeling of the recombinant enzyme.  
285 Unexpectedly, proHPSE labeling was slightly increased at moderate heparin concentrations  
286 (**Supplementary Fig. 10b**). Finally, we tested the ability of GlcUA to inhibit labeling of HPSE and  
287 proHPSE. No substantial inhibition of either proHPSE or HPSE labeling was observed at up to 20 mM  
288 GlcUA (**Supplementary Fig. 10c**), suggesting that GlcUA cannot occupy the active site of (pro)HPSE  
289 with sufficient affinity to prevent binding and reactivity of an ABP. Further subsite interactions may  
290 be required for binding of simple glucuronides to (pro)HPSE.

291 It has previously been demonstrated that proHPSE uptake by cells is a HS dependent process, and  
292 can be disrupted by addition of exogenous heparin<sup>43</sup>. To investigate possible roles for the proHPSE  
293 'binding pocket' in proHPSE uptake and maturation, we prelabeled recombinant proHPSE with  
294 either untagged ABP **6**, fluorescent ABPs **1** or **3**, or a mock DMSO control, and examined its uptake  
295 by fibroblasts at 90 or 180 min. In all cases, prelabeled proHPSEs were taken up and processed to  
296 mature HPSE, as evidenced by western blot and fluorescence of internalized **1** or **3** (**Supplementary**  
297 **Fig. 11**). These data indicate that the proHPSE 'pocket' does not participate in the HS interactions  
298 involved in cellular uptake, and that occupation of the proHPSE 'pocket' does not inhibit HPSE  
299 maturation.

## 300 Discussion

301 The important role of  $\beta$ -glucuronidases in human biology is highlighted by the pathologies  
302 associated with aberrant expression of these enzymes. Lack of GUSB activity leads to accumulation  
303 of glucuronide-containing GAGs within lysosomes in MPSVII (Sly Syndrome). Conversely,  
304 overexpression of HPSE leads to aberrant breakdown of HS in the ECM, causing increased cancer  
305 growth and metastasis. Accurate tracking of  $\beta$ -glucuronidase activities is an essential prerequisite  
306 for fully understanding their role in both physiological and disease states.

307 Here we have reported the design and application of novel  $\beta$ -glucuronidase configured ABPs, and  
308 demonstrated their broad utility for interrogating activities of these enzymes. We show that ABP  
309 profiling is a viable method to assay  $\beta$ -glucuronidase activity in a variety of samples, ranging from  
310 recombinant proteins, to complex cell, tissue and organ lysates. Fluorescent labeling provides a  
311 facile method for probing  $\beta$ -glucuronidases in tissues with sufficient expression, allowing for tracking  
312 of processes such as proenzyme uptake and processing, and how these are affected by biological or  
313 pharmacological perturbation. In tissues with lower enzyme abundance, we have demonstrated  
314 detection of  $\beta$ -glucuronidases using a proteomic approach, which is also applicable for the discovery  
315 of previously uncharacterized  $\beta$ -glucuronidase activities in biological samples.

316 Use of ABPs provides several advantages over more traditional methods to quantitate glycoside  
317 hydrolase activities. Compared to techniques such as western blotting, ABPs specifically detect  
318 active enzymes, rather than an entire protein complement which may include misfolded or inactive  
319 isoforms. Whilst fluorometric or colorimetric assays also provide assessments of enzyme activity,  
320 they cannot distinguish between overlapping activities in complex mixtures, which arise from several  
321 enzymes or enzyme isoforms active on the same substrate. Indeed, many carbohydrate processing  
322 enzymes are processed from precursors into one or more isoforms with differing activities<sup>23,28,44,45</sup>.  
323 ABP profiling allows for multiple activities to be visualized and their responses to perturbation or  
324 inhibition to be individually assessed *in situ*.

325 Many *endo*-glycosidases such as HPSE are inactive in traditional activity assays, necessitating the use  
326 of expensive specialized substrates and/or cumbersome assay procedures to follow their activities.  
327 The discovery that aziridine ABPs label HPSE paves the way for more rapid and practicable methods  
328 to assess the activity of this enzyme, and may inspire development of probes to assay other *endo*-  
329 glycosidases. Whilst this current generation of  $\beta$ -glucuronidase ABPs shows some off-target effects  
330 against GBA and GLB1, limiting their use in diagnostic applications, further optimization based upon  
331 the crystal structures of HPSE (and proHPSE) may lead to improved probes with increased potency  
332 and specificity. Optimization efforts will be aided by the use of competitive ABP techniques, which  
333 we have demonstrated to be a viable method for assessing selective inhibitors of individual  $\beta$ -  
334 glucuronidases.

335 ABPs also provide powerful tools for characterization of novel enzyme activities, which may escape  
336 detection in traditional biochemical experiments. The use of an ABP driven approach in this study  
337 lead us to the surprising observation that the HPSE precursor proHPSE is in principle catalytically  
338 competent, an entirely unanticipated outcome based on previous studies. We have reported the  
339 first structural views of proHPSE, illustrating how its 6 kDa linker restricts access to the active site  
340 cleft for HS substrates. This linker does not entirely block access to the catalytic residues of

341 proHPSE, but instead contributes to the formation of an *exo*-glycosidase like ‘binding pocket’, which  
342 can accommodate smaller molecules. It remains to be determined whether this proHPSE ‘pocket’ is  
343 simply a structural relic from evolutionary expansion of an ancestral GH79 active site loop, or if there  
344 are *bona fide* endogenous substrates which are hydrolyzed by proHPSE.

345 In conclusion, we have presented a set of ABPs for functional interrogation of  $\beta$ -glucuronidases in  
346 their native contexts. The application of ABP methodology to carbohydrate processing enzymes  
347 provides a powerful set of tools to study the activity of these key enzymes, and will contribute  
348 towards our understanding of fundamental processes in glycobiology.

#### 349 **Accession codes**

350 Coordinates and structure factors have been deposited in the Protein Data Bank under accession  
351 codes 5G0Q (AcGH79(wt)-5 complex), 5L77 (AcGH79(E287Q)-5 complex), 5L9Y (HPSE(wt)-5  
352 complex), 5L9Z (HPSE(E343Q)-5 complex), 5LA4 (*apo* proHPSE), 5LA7 (proHPSE-5 complex).

#### 353 **Acknowledgements**

354 We thank Diamond Light Source for access to beamlines i02, i03 and i04 (proposals mx-9948 and mx-  
355 13587), which contributed to the results presented here. We acknowledge the Netherlands  
356 Organization for Scientific Research (NWO, ChemThem Grant to J.M.F.G.A. and H.S.O.), the China  
357 Scholarship Council (CSC, PhD Grant to J.J.), the European Research Council (ErC-2011-AdG-290836  
358 to H.S.O.; ErC-2012-AdG-322942 to G.J.D.), and the Royal Society (Ken Murray Research  
359 Professorship to G.J.D) for financial support.

#### 360 **Author contributions**

361 L.W., J.M.F.G.A., H.S.O. and G.J.D. conceived and designed the experiments. J.J., M.A., W.D. and  
362 C.v.E. carried out synthesis of probes, with guidance from G.A.v.d.M. and J.D.C.C.. L.W. and Y.J.  
363 carried out protein expression and structural studies on enzyme-probe complexes. J.J., L.W., W.W.K.  
364 and C-L.K. carried out gel labeling experiments. J.J. and B.I.F. carried out proteomics experiments. C-  
365 L.K. and W.W.K. determined IC50 and kinetic parameters for ABPP inhibition. M.v.E. obtained tissue  
366 samples. L.W., J.J., H.S.O., and G.J.D. wrote the manuscript with input from all authors.

#### 367 **Competing financial interests**

368 The authors declare no competing financial interests.

#### 369 **Corresponding authors**

370 Correspondence to Gideon Davies or Herman Overkleef.

#### 371 **Methods and Supplementary Information**

372 Supplementary results containing Supplementary Tables 1 and 2, Supplementary Figures 1–12,  
373 Supplementary Notes 1 and 2 and Supplementary Data Set 1 are available in the online version of  
374 this paper.

375

376 **Main text references**

377

- 378 1. Khan, F.I. et al. Large scale analysis of the mutational landscape in beta-glucuronidase: A  
379 major player of mucopolysaccharidosis type VII. *Gene* **576**, 36-44 (2016).
- 380 2. Sly, W.S., Quinton, B.A., McAlister, W.H. & Rimoin, D.L. Beta glucuronidase deficiency: report  
381 of clinical, radiologic, and biochemical features of a new mucopolysaccharidosis. *J. Pediatr.*  
382 **82**, 249-257 (1973).
- 383 3. Naz, H. et al. Human beta-glucuronidase: structure, function, and application in enzyme  
384 replacement therapy. *Rejuvenation Res.* **16**, 352-363 (2013).
- 385 4. Rivara, S., Milazzo, F.M. & Giannini, G. Heparanase: a rainbow pharmacological target  
386 associated to multiple pathologies including rare diseases. *Future Med. Chem.* **8**, 647-680  
387 (2016).
- 388 5. Vlodavsky, I. et al. Significance of heparanase in cancer and inflammation. *Cancer*  
389 *Microenviron.* **5**, 115-132 (2012).
- 390 6. Cantarel, B.L. et al. The Carbohydrate-Active EnZymes database (CAZy): an expert resource  
391 for Glycogenomics. *Nucleic. Acids. Res.* **37**, D233-238 (2009).
- 392 7. Jain, S. et al. Structure of human beta-glucuronidase reveals candidate lysosomal targeting  
393 and active-site motifs. *Nat. Struct. Biol.* **3**, 375-381 (1996).
- 394 8. Wu, L., Viola, C.M., Brzozowski, A.M. & Davies, G.J. Structural characterization of human  
395 heparanase reveals insights into substrate recognition. *Nat. Struct. Mol. Biol.* **22**, 1016-1022  
396 (2015).
- 397 9. Jiang, J. et al. Detection of Active Mammalian GH31 alpha-Glucosidases in Health and  
398 Disease Using In-Class, Broad-Spectrum Activity-Based Probes. *ACS Cent. Sci.* **2**, 351-358  
399 (2016).
- 400 10. Kallemeyn, W.W. et al. Novel activity-based probes for broad-spectrum profiling of retaining  
401 beta-exoglucosidases in situ and in vivo. *Angew. Chem. Int. Ed.* **51**, 12529-12533 (2012).
- 402 11. Willems, L.I. et al. Potent and selective activity-based probes for GH27 human retaining  
403 alpha-galactosidases. *J. Am. Chem. Soc.* **136**, 11622-11625 (2014).
- 404 12. Witte, M.D. et al. Ultrasensitive in situ visualization of active glucocerebrosidase molecules.  
405 *Nat. Chem. Biol.* **6**, 907-913 (2010).
- 406 13. Jiang, J. et al. In vitro and in vivo comparative and competitive activity-based protein  
407 profiling of GH29 alpha-l-fucosidases. *Chem. Sci.* **6**, 2782-2789 (2015).
- 408 14. Kwan, D.H. et al. Chemoenzymatic synthesis of 6-phospho-cyclophellitol as a novel probe of  
409 6-phospho-beta-glucosidases. *FEBS Lett.* **590**, 461-468 (2016).
- 410 15. Barglow, K.T. & Cravatt, B.F. Activity-based protein profiling for the functional annotation of  
411 enzymes. *Nat. Methods* **4**, 822-827 (2007).
- 412 16. Li, K.Y. et al. Exploring functional cyclophellitol analogues as human retaining beta-  
413 glucosidase inhibitors. *Org. Biomol. Chem.* **12**, 7786-7791 (2014).
- 414 17. Koshland, D.E. Stereochemistry and the mechanism of enzymatic reactions. *Biol. Rev.* **28**,  
415 416-436 (1953).
- 416 18. Willems, L.I. et al. From covalent glycosidase inhibitors to activity-based glycosidase probes.  
417 *Chemistry* **20**, 10864-10872 (2014).
- 418 19. Michikawa, M. et al. Structural and biochemical characterization of glycoside hydrolase  
419 family 79 beta-glucuronidase from *Acidobacterium Capsulatum*. *J. Biol. Chem.* **287**, 14069-  
420 14077 (2012).
- 421 20. Baici, A., Schenker, P., Wachter, M. & Ruedi, P. 3-Fluoro-2,4-dioxo-3-phosphadecalins as  
422 inhibitors of acetylcholinesterase. A reappraisal of kinetic mechanisms and diagnostic  
423 methods. *Chem. Biodivers.* **6**, 261-282 (2009).
- 424 21. Speciale, G., Thompson, A.J., Davies, G.J. & Williams, S.J. Dissecting conformational  
425 contributions to glycosidase catalysis and inhibition. *Curr. Opin. Struct. Biol.* **28**, 1-13 (2014).

- 426 22. Gloster, T.M. & Davies, G.J. Glycosidase inhibition: assessing mimicry of the transition state.  
427 *Org. Biomol. Chem.* **8**, 305-320 (2010).
- 428 23. Islam, M.R., Grubb, J.H. & Sly, W.S. C-terminal processing of human beta-glucuronidase. The  
429 propeptide is required for full expression of catalytic activity, intracellular retention, and  
430 proper phosphorylation. *J. Biol. Chem.* **268**, 22627-22633 (1993).
- 431 24. Ono, M. et al. Phosphorylation of beta-glucuronidases from human normal liver and  
432 hepatoma by cAMP-dependent protein kinase. *J. Biol. Chem.* **263**, 5884-5889 (1988).
- 433 25. Forrest, A.R. et al. A promoter-level mammalian expression atlas. *Nature* **507**, 462-470  
434 (2014).
- 435 26. Weiss, D.J., Liggitt, D. & Clark, J.G. Histochemical Discrimination of Endogenous Mammalian  
436 beta-galactosidase Activity from that Resulting from lac-Z Gene Expression. *Histochem. J.* **31**,  
437 231-236 (1999).
- 438 27. Peterson, S.B. & Liu, J. Multi-faceted substrate specificity of heparanase. *Matrix Biol.* **32**,  
439 223-227 (2013).
- 440 28. Fairbanks, M.B. et al. Processing of the human heparanase precursor and evidence that the  
441 active enzyme is a heterodimer. *J. Biol. Chem.* **274**, 29587-29590 (1999).
- 442 29. Abboud-Jarrous, G. et al. Cathepsin L is responsible for processing and activation of  
443 proheparanase through multiple cleavages of a linker segment. *J. Biol. Chem.* **283**, 18167-  
444 18176 (2008).
- 445 30. Takahashi, K. et al. Characterization of CAA0225, a novel inhibitor specific for cathepsin L, as  
446 a probe for autophagic proteolysis. *Biol. Pharm. Bull.* **32**, 475-479 (2009).
- 447 31. Shaw, E., Mohanty, S., Colic, A., Stoka, V. & Turk, V. The affinity-labelling of cathepsin S with  
448 peptidyl diazomethyl ketones. Comparison with the inhibition of cathepsin L and calpain.  
449 *FEBS Lett.* **334**, 340-342 (1993).
- 450 32. Nadav, L. et al. Activation, processing and trafficking of extracellular heparanase by primary  
451 human fibroblasts. *J. Cell Sci.* **115**, 2179-2187 (2002).
- 452 33. Vlodaysky, I. et al. Expression of heparanase by platelets and circulating cells of the immune  
453 system: possible involvement in diapedesis and extravasation. *Invas. Metast.* **12**, 112-127  
454 (1992).
- 455 34. McKenzie, E. et al. Biochemical characterization of the active heterodimer form of human  
456 heparanase (Hpa1) protein expressed in insect cells. *Biochem. J.* **373**, 423-435 (2003).
- 457 35. Islam, M.R. et al. Active site residues of human beta-glucuronidase. Evidence for Glu(540) as  
458 the nucleophile and Glu(451) as the acid-base residue. *J. Biol. Chem.* **274**, 23451-23455  
459 (1999).
- 460 36. Kallemeijn, W.W. et al. A sensitive gel-based method combining distinct cyclophellitol-based  
461 probes for the identification of acid/base residues in human retaining beta-glucosidases. *J.*  
462 *Biol. Chem.* **289**, 35351-35362 (2014).
- 463 37. Niphakis, M.J. & Cravatt, B.F. Enzyme inhibitor discovery by activity-based protein profiling.  
464 *Annu. Rev. Biochem.* **83**, 341-377 (2014).
- 465 38. Kawase, Y. et al. A-72363 A-1, A-2, and C, novel heparanase inhibitors from *Streptomyces*  
466 *nobilis* SANK 60192, II. Biological activities. *J. Antibiot. (Tokyo)* **49**, 61-64 (1996).
- 467 39. Rabenstein, D.L. Heparin and heparan sulfate: structure and function. *Nat. Prod. Rep.* **19**,  
468 312-331 (2002).
- 469 40. Davies, G.J., Wilson, K.S. & Henrissat, B. Nomenclature for sugar-binding subsites in glycosyl  
470 hydrolases. *Biochem. J.* **321 ( Pt 2)**, 557-559 (1997).
- 471 41. Bohlmann, L. et al. Functional and structural characterization of a heparanase. *Nat. Chem.*  
472 *Biol.* **11**, 955-957 (2015).
- 473 42. Abboud-Jarrous, G. et al. Site-directed mutagenesis, proteolytic cleavage, and activation of  
474 human proheparanase. *J. Biol. Chem.* **280**, 13568-13575 (2005).
- 475 43. Gingis-Velitski, S. et al. Heparanase uptake is mediated by cell membrane heparan sulfate  
476 proteoglycans. *J. Biol. Chem.* **279**, 44084-44092 (2004).

- 477 44. Moreland, R.J. et al. Lysosomal acid alpha-glucosidase consists of four different peptides  
478 processed from a single chain precursor. *J. Biol. Chem.* **280**, 6780-6791 (2005).
- 479 45. Tollersrud, O.K. et al. Purification of bovine lysosomal alpha-mannosidase, characterization  
480 of its gene and determination of two mutations that cause alpha-mannosidosis. *Eur. J.*  
481 *Biochem.* **246**, 410-419 (1997).
- 482

483 **Figure 1** Concept and design of  $\beta$ -glucuronidase targeting ABPs. **a** Generalized schematic of double-  
484 displacement mechanism employed by retaining  $\beta$ -glycosidases. **b** Mechanism based inhibition by  
485 cyclophellitol derived ABPs. **c** Structures of cyclophellitol, cyclophellitol aziridine, and  $\beta$ -  
486 glucuronidase specific ABPs used in this study. Numbering of atomic positions is shown on  
487 cyclophellitol.

488 **Figure 2** ABP labeling of retaining  $\beta$ -glucuronidases in human spleen lysates. **a** Three isoforms of  
489 GUSB are fluorescently labeled by Cy5 ABP **3** in human wild type spleen, along with off target  
490 labeling of the  $\beta$ -glucosidase GBA. Labeling of these proteins by **3** can be competed for by biotin ABP  
491 **4**. GBA labeling in wild type spleen is also specifically competed for by **9**, and is absent in lysates  
492 from Gaucher spleen. **b** Silver stained SDS-PAGE gel of proteins captured from human wild type  
493 spleen by labeling with **4** (with or without competition by **9**) followed by streptavidin pulldown.  
494 Glycosidase enzymes identified in each gel band by proteomic profiling are listed. Full proteomics  
495 datasets for proteins identified by ABP pulldowns are available in **Supplementary Data Set 1**.

496 **Figure 3** Human HPSE is readily visualized by fluorescent  $\beta$ -glucuronidase ABPs. **a** Induced  
497 overexpression of HPSE and proHPSE in HEK293T cells can be tracked by ABP **3**. Fluorescent labeling  
498 by **3** correlates with bands from western blotting using an anti-HPSE antibody. **b** ABP tracking of  
499 uptake and processing of proHPSE to HPSE by fibroblast cells. **c** Endogenous HPSE in human platelets  
500 can be labeled by **3**, along with the same GUSB bands as observed in spleen. **d** pH dependence of  
501 HPSE and GUSB labeling in platelet lysates, demonstrating how general or specific enzyme labeling  
502 can be achieved by modulating pH.

503 **Figure 4** General and endo-specific inhibition of  $\beta$ -glucuronidases assessed by competitive ABP  
504 profiling. **a** Monosugar like  $\beta$ -glucuronidase inhibitor siastatin B can be accommodated *exo*- and  
505 *endo*- acting  $\beta$ -glucuronidase active sites, and competes out ABP **3** labeling of both GUSB and HPSE.  
506 **b** Polysaccharide heparin (**12**) only inhibits ABP labeling of HPSE, due to its inability to interact with  
507 the *exo*- configured active site of GUSB. **c** Selective HPSE inhibition is also achieved by heparan  
508 sulfate (**13**). Competitive ABP gels shown are representative of three technical replicates. Plots are  
509 mean values  $\pm$  s.d. (N=3) for quantitated HPSE and GUSB fluorescent band intensities, normalized to  
510 band intensities in the no inhibitor control lane. For all plots, quantitated GUSB fluorescence is a sum  
511 of the three assigned bands. n.d.: not determined.

512 **Figure 5** 3-dimensional structure of proHPSE, and its active site interactions with ABP **5**. **a** Ribbon  
513 and surface diagram of proHPSE, demonstrating steric blockage of the HPSE binding cleft by the 6  
514 kDa linker. An exposed 'pocket' in proHPSE can still interact with small molecules such as **5**  
515 (highlighted pink for clarity). **b** ABP **5** in complex with proHPSE within its 'binding pocket'. The O4  
516 position, where HS substrates would extend in mature HPSE, is blocked by His155, contributed by  
517 the linker (colored in green). Density is REFMAC maximum-likelihood/ $\sigma_A$  weighted  $2Fo-Fc$  contoured  
518 to 0.38 electrons/ $\text{\AA}^3$ . **c** Schematic of H-bonding interactions between reacted **5** and proHPSE active  
519 site residues. Interactions are identical to those observed for the mature enzyme (**Supplementary**  
520 **Fig. 8a, b**), except for His155 proximal to O4 of the probe. (nuc.: nucleophile; a/b: acid base).

521

522 **Table 1** Apparent IC50 values for *in vitro* and *in situ* inhibition of  $\beta$ -glucuronidase activity by ABPs,  
523 and kinetic parameters for inhibition of AcGH79 by ABPs. Data are mean values  $\pm$  s.d. (N=3) from  
524 three biological replicates.

Compound	<i>In vitro</i> AcGH79 apparent IC50 (nM)	Kinetic Parameters (AcGH79) $k_i/K_i$ ( $\mu\text{M}^{-1}\text{min}^{-1}$ )	<i>In situ</i> fibroblast apparent IC50 ( $\mu\text{M}$ )
1	0.6 $\pm$ 0.2	25.0 $\pm$ 0.7	>15
2	0.8 $\pm$ 0.2	18.2 $\pm$ 0.9	1.7 $\pm$ 0.6
3	1.1 $\pm$ 0.1	14.0 $\pm$ 0.8	1.8 $\pm$ 0.4
4	0.4 $\pm$ 0.02	5.5 $\pm$ 0.2	>15
5	0.1 $\pm$ 0.01	18.8 $\pm$ 0.7	>15
6	4.6 $\pm$ 0.03	3.5 $\pm$ 0.2	>15
7	33.4 $\pm$ 3.1	0.49 $\pm$ 0.05	>15

525



526 **Methods**

527 **Chemical probes and inhibitors**

528 4MU-GlcUA, Leupeptin, Siastatin B, Hyaluronic Acid (**15**) and Chondroitin Sulfate (**16**) were obtained  
529 from Sigma Aldrich. CTSL inhibitors CAA0225 (**10**) and Z-FY(tBu)-DMK (**11**) were obtained from  
530 Merck. Heparin (**12**) and Heparan Sulfate (**13**) were obtained from Iduron. *N*-Acetyl-*O*-desulfated  
531 Heparin (**14**) was obtained from Dextra. Cyclophellitol, cyclophellitol aziridine<sup>46</sup> and ABP **9**<sup>10</sup> were  
532 synthesized according to described procedures. Syntheses of compounds **1–8** are described in  
533 **Supplementary Note 2.**

534 **Tissue and cell samples**

535 Gaucher patients were diagnosed on the basis of reduced GBA activity and demonstration of an  
536 abnormal genotype. Spleens from a normal subject and a patient suffering from type 1 Gaucher  
537 disease were collected after splenectomy and frozen at –80 °C until use. Platelets were collected  
538 from healthy donors, using EDTA as the anti-coagulant. Platelet rich plasma (PRP) was prepared by  
539 centrifugation at 100 g for 20 min at 22 °C to remove red and white blood cells. Platelets were  
540 isolated from PRP by centrifugation at 220 g for 10 min at 22 °C, and frozen at –80 °C until use.  
541 Approval for tissue collection was obtained from the Academisch Medisch Centrum (AMC) and  
542 University of York medical ethics committees. Informed consent was obtained from all donors.

543 Primary human fibroblasts (CC-2511) were obtained from Lonza. HEK293T cells (ATCC-CRL-3216)  
544 were obtained from the American Type Culture Collection (ATCC). Sf21 and High Five cells for  
545 protein production were obtained from Invitrogen. Cells were used as obtained from the supplier  
546 without further authentication. All cells used tested negative for mycoplasma contamination.

547 All tissue lysates were prepared in KPI buffer (25 mM potassium phosphate [pH 6.5], supplemented  
548 with 1 × cComplete protease inhibitor cocktail (Roche)). Cells/tissues were homogenized with a silent  
549 crusher S equipped with a type 7 F/S head (30,000 rpm, 3 × 7 sec) on ice. Lysate protein  
550 concentrations were determined with a Qubit 2.0 Fluorometer (Invitrogen) or Bradford assay using  
551 BSA as a standard. Lysates were stored in aliquots at –80 °C until use.

552 **Recombinant protein cloning, expression and purification**

553 *AcGH79*

554 The coding sequence of AcGH79 with an N-terminal 6×His tag was cloned into pET28a (Novagen),  
555 which was used to transform *E. coli* BL21-Gold(DE3) (Agilent). Transformants were grown at 37 °C in  
556 LB media containing 50 µg/mL kanamycin to an OD<sub>600</sub> of 0.8, induced by addition of 1 mM isopropyl  
557 β-D-1-thiogalactopyranoside, and protein production carried out at 25 °C for 12 h. Harvested  
558 cells were resuspended in 50 mL AcGH79 HisTrap buffer A (20 mM HEPES [pH 7.0], 200 mM NaCl, 5  
559 mM imidazole), lysed by sonication, and lysate clarified by centrifugation at 12000 g. Supernatant  
560 containing AcGH79 was filtered before loading onto a HisTrap 5 mL FF crude column (GE Healthcare)  
561 pre-equilibrated with AcGH79 HisTrap buffer A. The loaded HisTrap column was washed with 10  
562 column volumes (CV) of AcGH79 HisTrap buffer A, before eluting with AcGH79 HisTrap buffer B (20  
563 mM HEPES [pH 7.0], 200 mM NaCl, 400 mM imidazole) over a 20 CV linear gradient.

564 Fractions containing AcGH79 were pooled, concentrated using a 30 kDa cutoff Vivaspin concentrator  
565 (GE Healthcare) and further purified by size exclusion chromatography (SEC) using a Superdex 75  
566 16/600 column (GE Healthcare) in AcGH79 SEC buffer (20 mM HEPES [pH 7.0], 200 mM NaCl).  
567 Fractions containing AcGH79 were pooled and concentrated using a 30 kDa Vivaspin concentrator to  
568 a final concentration of 14.5 mg/mL, and flash frozen for use in further experiments.

569 E287Q mutagenesis was carried out using a PCR based method<sup>47</sup>. Mutant protein was purified using  
570 the same protocol as for wild type protein. Mutagenesis primers are listed in **Supplementary Table**  
571 **2**.

#### 572 *Mature HPSE*

573 Mature HPSE cloning, expression, purification was carried out as previously described<sup>8</sup>.

574 E343Q mutagenesis was carried out using a PCR based method. Mutant protein was purified using  
575 the same protocol as for wild type protein. Mutagenesis primers are listed in **Supplementary Table**  
576 **2**.

#### 577 *proHPSE*

578 Insect cells are unable to process proHPSE to mature HPSE, allowing the former to be isolated  
579 following expression. cDNA encoding for proHPSE, minus the first 35 amino acid codons comprising  
580 the native signal sequence, was cloned behind a 5' honeybee mellitin signal sequence, 6×His tag,  
581 and TEV cleavage site, into the pOMNIBac plasmid (Geneva Biotech) using SLIC<sup>48</sup>. pOMNIBac-  
582 proHPSE was used to generate recombinant bacmid using the Tn7 transposition method in  
583 DH10EMBacY cells<sup>49</sup> (Geneva Biotech). Baculovirus preparation and protein expression was carried  
584 out as previously described for mature HPSE.

585 For purification, 3 L of conditioned media was cleared of cells by centrifugation at 400 g for 15 min at  
586 4 °C, followed by further clearing of debris by centrifugation at 4000 g for 60 min at 4 °C. DTT (1  
587 mM) and AEBSF (0.1 mM) were added to cleared media, which was loaded onto a HiTrap Sepharose  
588 SP FF 5 mL column (GE healthcare) pre-equilibrated in IEX buffer A (20 mM HEPES [pH 7.4], 100 mM  
589 NaCl, 1 mM DTT). The loaded SP FF column was washed with 10 CV of IEX buffer A, and eluted with  
590 a linear gradient over 30 CV using IEX buffer B (20 mM HEPES [pH 7.4], 1.5 mM NaCl, 1 mM DTT).  
591 proHPSE containing fractions were pooled and diluted 10 fold into proHPSE HisTrap buffer A (20 mM  
592 HEPES [pH 7.4], 500 mM NaCl, 20 mM Imidazole, 1 mM DTT), before loading onto a HisTrap 5 mL FF  
593 crude column pre-equilibrated in proHPSE HisTrap buffer A. The loaded HisTrap column was washed  
594 with 10 CV HisTrap buffer A, and eluted with a linear gradient over 20 CV using proHPSE HisTrap  
595 buffer B (20 mM HEPES [pH 7.4], 500 mM NaCl, 1 M Imidazole, 1 mM DTT). proHPSE containing  
596 fractions were pooled and concentrated to ~2 mL using a 30 kDa cutoff Vivaspin concentrator, and  
597 treated with 5 µL EndoH (NEB) and 5 µL AcTEV protease (Invitrogen) for >72 h. Digested protein was  
598 purified by SEC using a Superdex S75 16/600 column in proHPSE SEC buffer (20 mM HEPES [pH 7.4],  
599 200 mM NaCl, 1 mM DTT). proHPSE containing fractions were concentrated to 10 mg/mL using a 30  
600 kDa Vivaspin concentrator, exchanged into IEX buffer A via at least 3 rounds of  
601 dilution/reconcentration, and flash frozen for use in further experiments.

602

603 **Overexpression of HPSE in HEK293T cells**

604 pGEn1-HPSE and pGEn2-HPSE plasmids were obtained from the DNASU repository<sup>50</sup>. HEK293T cells  
605 were grown in DMEM media supplemented with 10% newborn calf serum (NBCS; Sigma) and 1%  
606 penicillin/streptomycin (Sigma). 20 µg DNA was transfected into HEK293T cells at ~80% confluence,  
607 using linear PEI at a ratio of 3:1 (PEI:DNA). At relevant timepoints cells were washed with PBS,  
608 harvested into KPI buffer using a cell scraper, and pelleted by centrifugation at 200 g for 5 min at 4  
609 °C. Cell pellets were frozen at –80 °C prior to use.

610 For CTSL inhibition experiments, transfections were carried out as above, except media was  
611 exchanged 7 h post transfection for DMEM supplemented with CTSL inhibitor or vehicle only control  
612 (0.05% v/v EtOH).

613 **proHPSE fibroblast uptake experiment**

614 Primary human fibroblasts were grown in DMEM/F12 media supplemented with 10% NBCS and 1%  
615 penicillin/streptomycin. Cells at 80% confluence were washed with PBS, before exchanging into  
616 DMEM/F12 media supplemented with proHPSE to 10 µg/mL final concentration. At relevant  
617 timepoints, cells were washed with ice cold PBS twice, harvested into KPI buffer using a cell scraper,  
618 and pelleted by centrifugation at 200 g for 5 min at 4 °C. Cell pellets were stored at –80 °C prior to  
619 use.

620 For uptake experiments with prelabeled proHPSEs, prelabeling was carried out in Mcllvaine  
621 citrate/phosphate buffer [pH 5.0], 300 mM NaCl in 200 µL volume, using 50 µM proHPSE and 200  
622 µM ABP. Reactions were incubated for 1 h for 37 °C, then excess ABP removed by desalting using a  
623 40 kDa MWCO Zeba spin column (Thermo). Extent of prelabeling by **1** and **3** was quantified by  
624 comparison of protein and fluorophore UV/Vis absorption values. Extent of prelabeling by **6** was  
625 estimated by testing residual reactivity to **3** (**Supplementary Fig. 11b**).

626 **Enzyme activity and inhibition assays**

627 Recombinant AcGH79 enzyme activity was assayed using 1.67 ng protein in 150 mM Mcllvaine buffer  
628 [pH 5.0]. To determine apparent IC50 values, 25 µL AcGH79 was preincubated with a range of  
629 inhibitor dilutions for 30 min at 37 °C, followed by addition of 100 µL 4MU-GlcUA solution to give  
630 final concentrations of 260 pM AcGH79 and 2.5 mM 4MUGlcUA. Reactions were carried out for 30  
631 min at 37 °C, quenched with 200 µL of 1 M NaOH-glycine [pH 10.3], and 4-MU fluorescence  
632 measured using a LS55 Fluorometer (Perkin Elmer) at  $\lambda_{ex}$  366 nm and  $\lambda_{em}$  445 nm. Apparent IC50  
633 values were determined in Prism (GraphPad) using a one phase decay function.

634 Kinetic parameters for inhibition of AcGH79 were determined using a continuous method  
635 (**Supplementary Note 1**; also Ref. 20). AcGH79 was added to pre-warmed mixtures of 4MU-GlcUA  
636 and ABP, to give final concentrations of 260 pM AcGH79 and 2.5 mM 4MU-GlcUA in a final reaction  
637 volume of 125 µL. Reactions were incubated at 37°C. At set timepoints, aliquots of reaction mixture  
638 were transferred to 96-well microplates (Greiner), quenched with 1 M NaOH-glycine [pH 10.3], and  
639 4MU fluorescence measured immediately using a LS-55 Fluorometer. The apparent rate of  
640 inactivation ( $k_{obs}$ ) was calculated for each ABP concentration by fitting with the exponential function  
641  $[4MU]=A*(1-e^{(-k_{obs}*t)})$ . The resulting plot of  $k_{obs}$  vs. [ABP] was fitted using a linear function, which

642 gives the combined apparent inhibition parameter  $k_i/K'_i$  as the gradient.  $k_i/K_i$  was derived from  $k_i/K'_i$ ,  
643 by correcting for the presence of competing 4MU-GlcUA substrate, using the relationship  
644  $K'_i = K_i(1 + [S]/K_M)$ , where  $[S] = 2.5$  mM and  $K_M = 18.2$   $\mu$ M. All fittings were carried out using Prism.

645 *In situ* fibroblast IC50s were determined by incubating human fibroblast cells with a range of  
646 inhibitor dilutions for 2 hours, followed by 3  $\times$  washing with PBS and harvesting into KPI buffer  
647 supplemented with 0.1% Triton X-100. Harvested cells were pelleted by centrifugation at 200 g for 5  
648 min at 4  $^{\circ}$ C, and pellets stored at  $-80$   $^{\circ}$ C prior to use. Enzymatic reactions and apparent IC50  
649 calculations were performed as described for the *in vitro* IC50 determination experiments, but with  
650 5  $\mu$ g of total lysate protein per reaction.

### 651 **Fluorescent labeling**

652 Initial labeling reactions were carried out in Mcllvaine buffer [pH 5.0], except for pH range  
653 experiments, which were carried out in Mcllvaine buffer at the stated pHs. Typically 200 fmol  
654 recombinant protein was used for labeling AcGH79, HPSE and proHPSE (20 nM in 10  $\mu$ L final reaction  
655 volume). 20  $\mu$ g total protein was used for labeling cell/tissue lysates, except for HEK293T  
656 overexpression experiments, where 10  $\mu$ g total protein was used. Unless otherwise specified,  
657 labeling reactions were carried out by incubation with 100 nM fluorescent ABP in a reaction volume  
658 of 10  $\mu$ L for 1 h at 37  $^{\circ}$ C. Gels were scanned for ABP-emitted fluorescence using a Bio-Rad ChemiDoc  
659 MP imager with the settings: Cy2 ( $\lambda_{EX}$  470 nm, bandpass 30 nm;  $\lambda_{EM}$  530 nm, bandpass 28 nm) for **1**,  
660 Cy3 ( $\lambda_{EX}$  530 nm, bandpass 28 nm;  $\lambda_{EM}$  605 nm, bandpass 50 nm) for **2**, and Cy5 ( $\lambda_{EX}$  625 nm,  
661 bandpass 30 nm;  $\lambda_{EM}$  695 nm, bandpass 55 nm) for **3**.

662 For labeling rate experiments with pro- and mature HPSE, reactions were carried out as above,  
663 except 2 pmol recombinant protein was incubated with an equimolar amount of **3** at 37  $^{\circ}$ C. At  
664 specified timepoints, aliquots were removed from the reaction and denatured by boiling in Laemmli  
665 buffer. Denatured samples were stored on ice until all timepoints were collected, and run together  
666 on SDS-PAGE.

667 For competition experiments, optimized labeling reactions were carried out in Mcllvaine buffer [pH  
668 5.0], 300 mM NaCl. Protein samples were preincubated with inhibitor for 60 min at 37  $^{\circ}$ C prior to  
669 addition of 100 nM **3** for labeling. Platelet lysates were labeled at 37  $^{\circ}$ C for 1 h, recombinant  
670 proteins were labeled at 37  $^{\circ}$ C for 30 min. Following labeling, samples were denatured by boiling  
671 with Laemmli buffer for 5 min, and resolved by SDS-PAGE. Gels used for quantitation were scanned  
672 using a laser based Bio-Rad FX molecular imager, using the  $\lambda_{EX}$  635 nm external laser and 690BP  
673 emission filter. Images were analyzed using Quantity One (Bio-Rad). [Full-length images of all](#)  
674 [fluorescent gels used in this study can be found in Supplementary Fig. 12.](#)

### 675 **Chemical proteomics**

676 3 mg total protein from human wild type spleen, Gaucher spleen lysate, or human fibroblast lysate  
677 was incubated with either 10  $\mu$ M **4**, 10  $\mu$ M **9** for 30 min followed by 10  $\mu$ M **4**, or a vehicle only  
678 control (0.1% DMSO). All labeling reactions were carried out for 30 min at 37  $^{\circ}$ C in 500  $\mu$ L Mcllvaine  
679 buffer [pH 5.0], before denaturation by addition of 125  $\mu$ L 10% SDS and boiling for 5 min. Samples  
680 were prepared for pull-down with streptavidin coupled DynaBeads (Invitrogen) as described  
681 previously<sup>51</sup>. Following pull-down the samples were divided: 1/3 for in-gel digest and 2/3 for on-

682 bead digest. In-gel digest samples were eluted by boiling beads at 100 °C in 30 µL Laemmli buffer.  
683 Eluted proteins were separated by SDS-PAGE, and visualized by silver staining using the SilverQuest  
684 kit (Invitrogen). Bands were excised by scalpel and treated with gel digestion buffer (10 mM  
685 NH<sub>4</sub>HCO<sub>3</sub>, 5% ACN, 1mM CaCl<sub>2</sub>, 10 ng/µL trypsin) at 37 °C overnight. The resulting trypsin-digested  
686 peptides were desalted using stage tips, followed by evaporation of ACN and resuspension into 70  
687 µL sample solution (95:3:0.1 H<sub>2</sub>O:ACN:TFA) for LC-MS analysis. Samples were analyzed with a 2h  
688 gradient of 5–25% ACN on a nano-LC, hyphenated to an LTQ-Orbitrap. Peptides were identified via  
689 the Mascot protein search engine.

690 On bead digest samples were treated with trypsin digestion buffer (100 mM Tris [pH 7.8], 100 mM  
691 NaCl, 1 mM CaCl<sub>2</sub>, 2% ACN and 10 ng/µL trypsin) at 37 °C overnight with shaking. Trypsin digested  
692 peptides were desalted using stage tips, and analyzed as above. For identification of GUSB active-site  
693 peptides, trypsin digested beads were further treated with endoproteinase Glu-C digestion buffer  
694 (100 ng/µL Glu-C in PBS) at 37 °C overnight with shaking. Digested peptides were desalted and  
695 analyzed as above.

696 Peptide identification data were stringently filtered at a false discovery rate (FDR) of 1% and an  
697 MS/MS assignment Mascot score >40. [Full proteomics data are available in Supplementary Data Set](#)  
698 [1](#). The data presented in **Supplementary Data Set 1** show: the ranking of the proteins by the protein  
699 score, the UniProt accession number, trivial name of the protein, protein score, protein mass  
700 predicted from the RNA sequence, the amino acid coverage of the protein achieved by MS/MS  
701 sequencing, the query number of the peptide in the LC/MS run, the experimentally determined m/z  
702 of the peptide, the measured molecular weight, the charge state z, the predicted molecular weight,  
703 the delta accuracy between predicted and experimentally determined mass, the MS/MS assignment  
704 Mascot score, the expectancy value, peptide sequence and emPAI value (which gives an  
705 approximate relative estimation of peptide abundance). [Full proteomics data are available in](#)  
706 [Supplementary Data Set 1](#).

## 707 **Western blotting**

708 Proteins resolved by SDS-PAGE were transferred to a PVDF membrane using a Trans-Blot Turbo  
709 system (BioRad). Membranes were blocked in 5% BSA for 1 h at rt, then incubated with anti-HPSE  
710 (AbCam ab59787) or anti-GUSB (AbCam ab103112) at 1:1000 dilution in 5% BSA at 4 °C overnight.  
711 Membranes were washed 3 × with TBST (50 mM Tris [pH 7.5], 150 mM NaCl, 0.05% Tween 20), then  
712 incubated with HRP conjugated goat-anti-rabbit (Sigma A0545) at 1:5000 dilution in 5% BSA for 1 h  
713 at room temperature. Membranes were washed again 3 × with TBST, blots visualized using  
714 Amersham prime ECL reagent (GE Healthcare), and recorded using a Bio-Rad ChemiDoc XRS. Full-  
715 length images of all blots used in this study can be found in **Supplementary Fig. 12**.

## 716 **Protein crystallization**

717 *AcGH79*

718 *AcGH79* was tested against a range of commercial crystallization screens. Well diffracting crystals of  
719 wild type *AcGH79* were obtained by the sitting drop vapor diffusion method at 20 °C using 0.8–1.2 M  
720 0.5:9.5 NaH<sub>2</sub>PO<sub>4</sub>:K<sub>2</sub>HPO<sub>4</sub> (v/v) at a protein:well ratio of 700:500 nL. Crystals of *AcGH79* E287Q  
721 mutant were obtained using 1.2–1.5 M 1.0:9.0 NaH<sub>2</sub>PO<sub>4</sub>:K<sub>2</sub>HPO<sub>4</sub> (v/v) at a protein:well ratio of

**Comment [L1]:** This seemed like a reasonable place to move this statement (from the Data Availability Statement below). However, if you think there is a better place for it in the Figure legend or in the running online methods, please move it.

**Comment [L2]:** Moved to slightly earlier in paragraph, just before the description of the columns in the data set.

Suppl data set 1 is also called out in relevant parts of the main text (e.g. L142) and the caption for Fig. 2.

**Comment [L3]:** This seemed like a reasonable place to move this statement (from the Data Availability Statement below). However, if you think there is a better place for it in the Figure legend or in the running online methods, please move it.

**Comment [L4]:** Removed the word 'gels', as this is the section about western blotting.

A similar statement about gels has been added to the previous page (L672), in the 'fluorescent labeling' subsection of the methods.

722 500:500 nL. Crystals typically appeared after 1 day. Crystals were cryoprotected using 2 M lithium  
723 sulfate prior to flash freezing in liquid N<sub>2</sub> for data collection.

724 *Mature HPSE*

725 Mature HPSE was crystallized and data collected as previously described<sup>8</sup>.

726 *proHPSE*

727 proHPSE at 10 mg/mL was tested against a range of commercial crystallization screens. Thin plate  
728 crystals were found in the JCSG screen, which were used to microseed subsequent rounds of crystal  
729 screening<sup>52</sup>. Well diffracting single crystals were obtained by the sitting drop vapor diffusion method  
730 at 20 °C using 100 mM succinate [pH 7.0], 17% PEG3350 and 1:250 diluted seed stock at a  
731 protein:seed:well ratio of 700:100:400 nL. Crystals typically appeared after 1 day and grew to  
732 maximum size within 10 days. proHPSE crystals were cryoprotected using mother liquor solution  
733 supplemented with 25% ethylene glycol prior to flash freezing in liquid N<sub>2</sub> for data collection.

#### 734 **Xray data collection and structure solution**

735 Xray diffraction data were collected at 100 K at beamlines i02 (5LA4, 5LA7), i03 (5G0Q, 5L77, 5L9Y)  
736 and i04 (5L9Z) of the Diamond Light Source UK. Reflections were autoprocessed with the xia2  
737 pipeline<sup>53</sup> of the CCP4 software suite, or manually processed using XDS<sup>54</sup> and Aimless<sup>55</sup>. Apo  
738 proHPSE was solved by molecular replacement with the mature HPSE model (5E8M) using MolRep<sup>56</sup>,  
739 followed by alternating rounds of manual model building and refinement using Coot and REFMAC5  
740 respectively<sup>57,58</sup>.

741 For all complexes with ABP **5**, crystals were soaked in their respective mother liquors supplemented  
742 with 2–5 mM **5** for 1–3 h at 20 °C. Soaked crystals were cryoprotected using their respective  
743 cryoprotectant solutions prior to flash freezing in liquid N<sub>2</sub> for data collection.

744 Complexes were solved by molecular replacement with their respective apo structures, followed by  
745 rounds of manual model building and refinement using Coot and REFMAC5. Ligand coordinates were  
746 built using jLigand<sup>59</sup>. Active site diagrams were generated using ccp4mg<sup>60</sup>. Ribbon and protein  
747 surface diagrams were generated using PyMOL.

#### 748 **Accession codes**

749 Coordinates and structure factors have been deposited in the Protein Data Bank under accession  
750 codes 5G0Q (AcGH79(wt)-**5** complex), 5L77 (AcGH79(E287Q)-**5** complex), 5L9Y (HPSE(wt)-**5**  
751 complex), 5L9Z (HPSE(E343Q)-**5** complex), 5LA4 (*apo* proHPSE), 5LA7 (proHPSE-**5** complex).

#### 752 **Data availability**

753 | All [other](#) data generated or analyzed during this study are included in this published article (and its  
754 Supplementary Information files), or are available from the corresponding authors on reasonable  
755 request.

756

757

**Comment [15]:** This is a verbatim repeat of L350-352. I originally added this information here as part of the data availability statement.

Is it still necessary?

758 **Methods references**

759

- 760 46. Li, K.-Y. et al. Synthesis of Cyclophellitol, Cyclophellitol Aziridine, and Their Tagged  
761 Derivatives. *Eur. J. Org. Chem.*, 6030–6043 (2014).
- 762 47. Zheng, L., Baumann, U. & Reymond, J.L. An efficient one-step site-directed and site-  
763 saturation mutagenesis protocol. *Nucleic Acids Res.* **32**, e115 (2004).
- 764 48. Li, M.Z. & Elledge, S.J. SLIC: a method for sequence- and ligation-independent cloning.  
765 *Methods Mol. Biol.* **852**, 51-59 (2012).
- 766 49. Berger, I., Fitzgerald, D.J. & Richmond, T.J. Baculovirus expression system for heterologous  
767 multiprotein complexes. *Nat. Biotechnol.* **22**, 1583-1587 (2004).
- 768 50. Seiler, C.Y. et al. DNASU plasmid and PSI:Biological-Materials repositories: resources to  
769 accelerate biological research. *Nucleic Acids Res.* **42**, D1253-1260 (2014).
- 770 51. Li, N. et al. Relative quantification of proteasome activity by activity-based protein profiling  
771 and LC-MS/MS. *Nat. Protoc.* **8**, 1155-1168 (2013).
- 772 52. D'Arcy, A., Bergfors, T., Cowan-Jacob, S.W. & Marsh, M. Microseed matrix screening for  
773 optimization in protein crystallization: what have we learned? *Acta Crystallogr. F* **70**, 1117-  
774 1126 (2014).
- 775 53. Winter, G. xia2: an expert system for macromolecular crystallography data reduction. *J.*  
776 *Appl. Crystallogr.* **43**, 186-190 (2010).
- 777 54. Kabsch, W. XDS. *Acta Crystallogr. D* **66**, 125-132 (2010).
- 778 55. Evans, P.R. & Murshudov, G.N. How good are my data and what is the resolution? *Acta*  
779 *Crystallogr. D* **69**, 1204-1214 (2013).
- 780 56. Vagin, A. & Teplyakov, A. Molecular replacement with MOLREP. *Acta Crystallogr. D* **66**, 22-25  
781 (2010).
- 782 57. Emsley, P., Lohkamp, B., Scott, W.G. & Cowtan, K. Features and development of Coot. *Acta*  
783 *Crystallogr. D* **66**, 486-501 (2010).
- 784 58. Murshudov, G.N. et al. REFMAC5 for the refinement of macromolecular crystal structures.  
785 *Acta Crystallogr. D* **67**, 355-367 (2011).
- 786 59. Lebedev, A.A. et al. JLigand: a graphical tool for the CCP4 template-restraint library. *Acta*  
787 *Crystallogr. D* **68**, 431-440 (2012).
- 788 60. McNicholas, S., Potterton, E., Wilson, K.S. & Noble, M.E.M. Presenting your structures: the  
789 CCP4mg molecular-graphics software. *Acta Crystallogr. D* **67**, 386-394 (2011).

790

791